优化技术以改善药物坚持和血压控制 (OPTIMA-BP) 发明与非裔美国人高血压成年人等待名单组:随机控制试验协议
Carolyn Harmon Still1, Carla Harwell2, Cheryl Killion1
1Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Nursing (Auckland, N.Z.)
|May 9, 2025
概括
这项研究测试了一种基于技术的干预 (OPTIMA-BP) 以改善非裔美国人的高血压控制. 该OPTIMA-BP方法旨在增强药物坚持和血压管理,以获得更好的健康结果.
科学领域:
- 心血管健康 心血管健康
- 医疗卫生技术 技术 技术
- 健康差异 在健康上的差异
背景情况:
- 对少数群体来说,高血压治疗的坚持是具有挑战性的.
- 基于技术的干预 (TBI) 为高血压自我管理提供了一个有希望的方法.
- 有效的血压控制可以带来更好的长期健康结果.
研究的目的:
- 评估基于技术的OPTIMA-BP干预措施的有效性.
- 为了改善血压控制,与健康相关的生活质量 (HRQOL) 和非裔美国人高血压的药物坚持.
- 评估高血压管理战略的长期合规性.
主要方法:
- 一项前性,双臂随机试验,涉及高血压的非洲裔美国老年人 (≥50岁).
- 参与者被随机 (1:1) 分给OPTIMA-BP干预 (n=104) 或等候名单对照组 (n=104) 12个月.
- 该OPTIMA-BP干预包括基于网络的教育模块,用于药物坚持的mHealth应用程序,家庭血压监测和护士咨询.
主要成果:
- 参与者招聘于2022年3月开始,目前仍在进行中.
- 预计初步调查结果将在2025年夏天发布.
- 主要终点是达到血压低于130/80mmHg和改善HRQOL.
结论:
- 基于技术的干预措施与标准护理相结合,可以改善血压控制.
- 这种方法为高风险人群中二次心血管疾病预防提供了一个独特的策略.
- 在非洲裔美国人中,OPTIMA-BP显示了提高高血压自我管理和结果的潜力.
相关概念视频
01:25Errors occurring during blood pressure monitoring
568
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
568
01:33Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:28Factors affecting Blood pressure
2.7K
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Physiological Factors:
2.7K
01:18Hypertension and Regulation of Blood Pressure
1.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.8K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
394
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
394